Follow-up data from 2 randomized trials: efficacy and safety of Upadacitinib in patients with moderate to severe atopic dermatitis. 18 Mar, 2022 | 07:48h | UTC Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology